[November 11, 2009] www.Xtremepicks.Com: Xtremepicks Alerts November 11, 2009 : ALTH, ABAX, RAMS and ATML Tweet (M2 PressWIRE Via Acquire Media NewsEdge) Xtremepicks.com Alerts include Allos Therapeutics, Inc. (Nasdaq: ALTH), Abaxis, Inc. (Nasdaq: ABAX), Aries Maritime Transport Limited (Nasdaq: RAMS) and Atmel(R) Corporation (Nasdaq: ATML) Allos Therapeutics, Inc. (Nasdaq: ALTH) trading at $6.12 on a volume of 449,818 shares In a press release out on November 11, Allos Therapeutics Announces New Data on FOLOTYN(TM) to be Presented at the American Society of Hematology Meeting WESTMINSTER, Colo., Nov 11, 2009 -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that abstracts from studies of FOLOTYN(TM) (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009. About Allos Therapeutics Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN(TM) (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other potential indications. Allos retains exclusive worldwide rights to FOLOTYN for all indications. Allos is headquartered in Westminster, Colo. For additional information, please visit www.allos.com. Abaxis, Inc. (Nasdaq: ABAX) trading at $22.93 per share on trading volume of 11,143 shares. In a press release out on November 11, Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum UNION CITY, Calif., Nov 11, 2009 -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Brenton Hanlon, Vice President, North American Medical Sales and Marketing, will present at the Sidoti & Company Second Annual New York Institutional Investor Forum on Friday, November 20, 2009 at 4:00 p.m. Eastern. The conference will be held at The Grand Hyatt Hotel in New York City. About Abaxis Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer. Aries Maritime Transport Limited (Nasdaq: RAMS) trading at $1.02 on a volume of 2,500 shares In a press release out on November 11, Aries Maritime Transport Limited Announces Third Quarter 2009 Earnings and Conference Call Information ATHENS, Greece, Nov 11, 2009 -- Aries Maritime Transport Limited (Nasdaq: RAMS) today announced its plans to release third quarter 2009 earnings on Monday, November 16, 2009, before the open of market trading, hosting a conference call the same day at 8:00 a.m. ET to discuss the results. The conference call will not include a question and answer session. About Aries Maritime Transport Limited Aries Maritime Transport Limited is an international shipping company that owns and operates products tankers, container vessels and drybulk carriers. For more information please visit our website at www.ariesmaritime.com. Atmel(R) Corporation (Nasdaq: ATML) trading at $3.97 on a volume of 1.58M shares In a press release out on November 11, Atmel Delivers Complete, Easy-to-Use Capacitive Touch Development Suite for AVR Microcontrollers --Includes new QT600 development kit, and QTouch(R) Studio for developing and embedding touch solutions as buttons, sliders and wheels to any AVR MCU design SAN JOSE, Calif., Nov 11, 2009 -- Atmel(R) Corporation (Nasdaq: ATML), a leader in touch and microcontroller-based solutions, today announced the release of the Atmel QTouch Suite, a complete development suite for capacitive touch buttons, sliders and wheels using AVR(R) microcontrollers. The Atmel QTouch Suite is a bundle that includes the new QT600 development kit and QTouch Studio, AVR Studio(R) and QTouch Library SW package for AVR microcontrollers. About Atmel Atmel is a worldwide leader in the design and manufacture of capacitive touch solutions, microcontrollers, advanced logic, mixed-signal, nonvolatile memory and radio frequency (RF) components. Leveraging one of the industry's broadest intellectual property (IP) technology portfolios, Atmel is able to provide the electronics industry with complete system solutions focused on consumer, industrial, security, communications, computing and automotive markets. Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience. Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at [email protected] Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm ((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS [ Back To TMCnet.com's Homepage ]